Abeona Therapeutics (ABEO) Current Deferred Revenue (2010 - 2021)

Abeona Therapeutics' Current Deferred Revenue history runs 12 years deep, the most recent figure standing at $296000.0 for Q4 2021.

• In Q4 2021, Current Deferred Revenue changed 0.0% year-over-year to $296000.0; the TTM figure through Dec 2021 stood at $296000.0 (changed 0.0% YoY), while the FY2021 annual figure was $296000.0, changed 0.0% from the prior year.
• Current Deferred Revenue was $296000.0 for Q4 2021 at Abeona Therapeutics, roughly flat from $296000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q4 2017 to a low of $296000.0 in Q4 2018.
• Historically, Current Deferred Revenue has averaged $560736.8 across 5 years, with a median of $296000.0 in 2018.
• The sharpest annual moves came in 2017 and 2018: Current Deferred Revenue surged 331.89% in 2017, then sank 88.62% in 2018.
• A 5-year view of Current Deferred Revenue shows it stood at $2.6 million in 2017, then tumbled by 88.62% to $296000.0 in 2018, then changed by 0.0% to $296000.0 in 2019, then changed by 0.0% to $296000.0 in 2020, then changed by 0.0% to $296000.0 in 2021.
• The last three Current Deferred Revenue figures came in at $296000.0 (Q4 2021), $296000.0 (Q3 2021), and $296000.0 (Q2 2021), per Business Quant data.